Lutetium (177lu) Vipivotide Tetraxetan

other

Identifier: CI-DRUG-00000753
Entity page: /drug/lutetium-177lu-vipivotide-tetraxetan ↗
Edges: 67

Neighbours: 18 cancers1 genes10 trials2 approvals
Drawn: 31 of 31 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Lutetium (177lu) Vipivotide Tetraxetan approved for …APPROVED_FORderived2 of 2
→ approved for	EMA · EU · 2022Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. EMA (EU) · approved · 2022-12-09 · Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for …	—	approved	not mapped	1	Regulatory	ema	open ↗

Lutetium (177lu) Vipivotide Tetraxetan targets …TARGETS1 of 1
→ targets	FOLH1	—	BINDING AGENT	—	1	Curated	chembl	graph →

Lutetium (177lu) Vipivotide Tetraxetan targets …TARGETS1 of 1

→ targets

FOLH1

—

BINDING AGENT

—

Curated

Lutetium (177lu) Vipivotide Tetraxetan investigated for …INVESTIGATED_FOR3 of 3
→ investigated for	Prostate Neoplasmsubtype	unknown	3	Prostate Neoplasm	1	Curated	chembl	graph →
→ investigated for	Adenoid Cystic Carcinomahistology	unknown	2	Adenoid Cystic Carcinoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	1	Neoplasm	1	Curated	chembl	graph →

Lutetium (177lu) Vipivotide Tetraxetan investigated in trials for …INVESTIGATED_IN_TRIALSderived18 of 18show fewer
→ investigated in trials for	Malignant Prostate Neoplasm 24 trials (17 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Castration-Resistant Prostate Carcinoma 15 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Castration-Resistant Prostate Carcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Prostate Neoplasmsubtype 7 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Prostate Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Prostate Adenocarcinoma 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Prostate Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Prostate Carcinoma 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Prostate Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Castration-Resistant Prostate Adenocarcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Castration-Resistant Prostate Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Clear Cell Renal Cell Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adenoid Cystic Carcinomahistology 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adenoid Cystic Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Astrocytoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Astrocytoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Hemispheric Glioma, H3 G34-Mutant 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Hemispheric Glioma, H3 G34-Mutant	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Midline Glioma, H3 K27-Altered 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Midline Glioma, H3 K27-Altered	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastoma, IDH-Wildtype 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Kidney Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Kidney Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasmcancer_family 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasm by Site 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm by Site	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →

Lutetium (177lu) Vipivotide Tetraxetan studied in …STUDIED_INderived10 of 43show all (up to 200)
→ studied in	NCT06095089Phase 1 · recruiting A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer · 43 trials list this drug (30 active)	—	—	Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05818683Phase 1 · recruiting A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer · 43 trials list this drug (30 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07650240Phase 2 · recruiting Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial · 43 trials list this drug (30 active)	—	—	Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03042468Phase 1/Phase 2 · completed Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC · 43 trials list this drug (30 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04689828Phase 3 · active not recruiting 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer · 43 trials list this drug (30 active)	—	—	Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05766371Phase 2 · recruiting Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer · 43 trials list this drug (30 active)	—	—	Prostate Neoplasm,Malignant Prostate Neoplasm,Prostate Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06632977Phase 2 · recruiting Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial · 43 trials list this drug (30 active)	—	—	Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07200830Phase 3 · recruiting Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial · 43 trials list this drug (30 active)	—	—	Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07698535Phase 2 · recruiting Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial · 43 trials list this drug (30 active)	—	—	Malignant Prostate Neoplasm,Castration-Resistant Prostate Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06200103Phase 2 · suspended Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer · 43 trials list this drug (30 active)	—	—	Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths